Drug intelligence / Profile preview

tyramine

Development stage
Phase 3
Modality
Small Molecules
Administration
Oral, Intravenous, Intra-arterial, Ophthalmic
01

Overview

Tyramine is an endogenous trace amine and orally bioactive small molecule monoamine that has been used mainly as a pharmacologic probe and challenge agent rather than as an approved therapeutic drug. It acts primarily as an indirect sympathomimetic: it is taken up into adrenergic nerve terminals and promotes displacement and release of stored norepinephrine, producing vasoconstrictor and pressor effects and other sympathetic responses. In the provided literature, tyramine was administered intra-arterially, intravenously, orally, and ophthalmically to study sympathetic neurotransmission, vascular responses, migraine biology, depressive illness, Parkinson disease, multiple system atrophy, autonomic failure, and metabolic responses in diabetes. Although tyramine is a real and publicly documented drug substance, it does not appear from the provided context to be an actively developed sponsor-owned therapeutic asset for a modern indication; its use in these sources is predominantly experimental, diagnostic-physiologic, or challenge-test based.

Other names
4-hydroxyphenethylaminep-tyraminetyramine hydrochloridetyramine sulfate
02

Targets

VMAT2 (Vesicular monoamine transporter 2)ADRB1 (β1)TAAR1 (Trace amine-associated receptor 1)

Beyond the preview

Go deeper on tyramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tyramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call